PLI bulk drugs scheme: approved API manufacturing projects in Telangana
Rajya Sabha reply lists Telangana’s approved API manufacturing capacity under two Production Linked Incentive schemes for pharmaceuticals.
- The schemes aim to encourage domestic manufacture of critical pharmaceutical inputs and strengthen supply security.
- Telangana has become a notable state for approved API manufacturing projects and production units under the pharmaceutical incentive framework.
What happened
The Ministry of Chemicals and Fertilizers has informed the Rajya Sabha that Telangana has received approvals under two pharmaceutical incentive schemes: the Production Linked Incentive scheme for bulk drugs and the Production Linked Incentive scheme for pharmaceuticals. The reply matters because it shows where India’s push for domestic manufacturing of Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates (DIs) is translating into industrial capacity.
Background and earlier position
UPSC can frame this topic around the design and implementation of Production Linked Incentive schemes, the objective of building domestic capacity in Active Pharmaceutical Ingredients, and the policy challenge of reducing import dependence in critical pharmaceutical inputs. A mains answer can also discuss centre-state industrial clustering, supply-chain resilience, and the limits of incentive-led manufacturing expansion.
Related dispatches
